Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen Idec
- 23 Nov 2011 Planned end date changed from 1 Feb 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 23 Jun 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Nov 2010 New trial record